News - regorafenib, Pharmaceutical

Filter

Current filters:

regorafenibPharmaceutical

Popular Filters

News briefs from Sanofi, Bayer, GlaxoSmithKline and Novartis

21-12-2012

French drug major Sanofi (Euronext: SAN) has entered into a binding agreement to acquire the animal health…

BayerDosch PharmaceuticalsExjadeFlonaseGlaxoSmithKlineLegalMergers & AcquisitionsMerialNovartisOncologyPharmaceuticalregorafenibRegulationRespiratory and PulmonarySanofi

Bayer's regorafenib overcomes resistance in patients with rare sarcoma

22-11-2012

A new targeted drug - German drug major Bayer's (BAYN: DE) regorafenib (trade name Stivarga) - demonstrated…

BayerBiotechnologyOncologyPharmaceuticalregorafenibResearchStivarga

Bayer's Stivarga races to FDA approval on the heels of Zaltrap

07-10-2012

The earlier than expected US Food and Drug Administration approval of German drug major Bayer's (BAYN:…

BayerBiotechnologyMarkets & MarketingNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibRegulationSanofiStivargaZaltrap

Early FDA approval for Bayer's Stivarga in advanced colorectal cancer

28-09-2012

Bayer said Stivarga will be ready for distribution as soon as today (September 28 and set a wholesale…

BayerNorth AmericaOncologyPharmaceuticalregorafenibRegulationStivarga

Bayer's regorafenib gets priority review for CRC in Japan

13-09-2012

Germany's Bayer (BAYN: DE) say that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted…

Asia-PacificBayerOncologyPharmaceuticalregorafenibRegulation

Bayer files NDA for regorafenib for the treatment of GIST

31-08-2012

The US subsidiary of Germany's Bayer (BAYB: DE) has submitted a New Drug Application to the US Food and…

BayerBiotechnologyNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibRegulation

News briefs: US priority review for regorafenib; Ph IIb blisibimod data

29-06-2012

Bayer HealthCare, a US unit of Germany's Bayer (BAYN: DE) and partner Onyx Pharmaceuticals (Nasdaq: ONXX)…

Anthera PharmaceuticalsBayerBiotechnologyblisibimodOncologyOnyx PharmaceuticalsPharmaceuticalRare diseasesregorafenibRegulationResearch

More news from ASCO meeting

05-06-2012

More positive late-stage clinical data continued to roll out at the Annual Meeting of the American Society…

AlimtaBayerdabrafenibEli LillyGlaxoSmithKlineOncologyPharmaceuticalregorafenibResearchtrametinib

News briefs: GlaxoSmithKline and Bayer

24-05-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) has said it would not proceed with its $2.59 billion hostile…

Antibiotics and Infectious diseasesBayerGlaxoSmithKlineMergers & AcquisitionsOncologyPharmaceuticalregorafenibRegulationResearch

Bayer cancer drug candidate regorafenib improves survival in GIST

04-04-2012

German drug major Bayer (BAY: DE) yesterday announced positive results from its Phase III trial GRID…

BayerOncologyPharmaceuticalregorafenibRegulationResearch

Bayer’s Xarelto OKed in Japan; promising regorafenib data

19-01-2012

Bayer Healthcare, a unit of Germany’s Bayer AG (BAY: DE), had a couple of good news item to report…

BayerCardio-vascularOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibRegulationResearchXarelto

Bayer boasts four potential pipeline blockbusters

21-12-2011

German drugs and crop and material sciences group Bayer (BAT: DE) said yesterday that it plans to continue…

AlpharadinBayerCardio-vascularEyleaFinancialMarkets & MarketingOncologyOphthalmicsPharmaceuticalregorafenibResearchXarelto

Bayer halts regorafenib trial for colorectal cancer on good Ph III results

27-10-2011

USA-based Bayer HealthCare Pharmaceuticals, a subsidiary of Germany’s Bayer AG (BAY: DE), has announced…

BayerOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibResearch

Bayer settles with Onyx over Nexavar and regorafenib with $160 million payment

13-10-2011

US drugmaker Onyx Pharmaceuticals (Nasdaq: ONXX) and German pharma major Bayer HealthCare, a unit of…

BayerLegalLicensingNexavarOncologyOnyx PharmaceuticalsPharmaceuticalregorafenib

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top